歐康維視生物(01477.HK)OT-202II期臨床試驗達到主要終點 料啟動III期臨床試驗
歐康維視生物(01477.HK)公布,一款公司自研治療乾眼症的同類首創新藥OT-202(酪氨酸激(酉每)抑制劑)的II期臨床試驗已成功完成揭盲,並已收集所有相關數據,標誌著該藥已達到II期臨床試驗的主要臨床終點,即接受該藥物治療的治療組第56天角膜染色評分較基線的好轉優於安慰劑組。該藥物在安全性及療效方面展現出積極的結果。公司預期近期將啟動III期臨床試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.